This study aims to assess whether the use of the METHIS digital platform using a patient-centered approach contributes to an improvement in the quality of life, mental health and physical activity of patients with multimorbidity followed up in Primary Health Care. Practices will be randomly allocated between: providing access to consultations through the METHIS platform (intervention) or following patients by the traditional method (control). They will complete questionnaires on quality of life, mental health and report the number of steps taken, at the beginning and end of the study.

Start Date01 Jun 2025

Sponsor / Collaborator

Universidade Nova de Lisboa

[+2]

NCT07021144

/ RecruitingNot ApplicableIIT

VA|PREVENTION: Randomized Controlled Trial of a Person-Centred Digital Intervention to Prevent Diabetes in High-Risk Adults

The goal of this clinical trial is to help prevent the development of type 2 diabetes (T2D) in adults who are at high risk. The study will test a digital intervention called VA|PREVENTION, a web application designed to support and promote healthy behaviour changes known has T2D risk factors, such as physical activity, diet, and sedentary behaviuor. The main questions this study will explore are:• Is the VA|PREVENTION web app, which includes a virtual human coach, effective in preventing type 2 diabetes?• Can the VA|PREVENTION web app be successfully implemented in real-world settings?• Is the VA|PREVENTION web app cost-effective?• Is it safe for participants to use?To answer these questions, the study team will compare the VA|PREVENTION web app to an openly available guidebook that provides standard information about preventing type 2 diabetes.Participants will complete the following activities:
* Participants will be randomly assigned to one of two groups: one group will use the VA|PREVENTION app, while the other group will have access to an openly accessible guidebook on T2D prevention.
* Participants will be in the study for 10 months.
* Participants will be assessed at the start of the study (baseline), and again at 4 months and 10 months.
* Assessments will include body measurements (such as weight, height, and waist circumference), physical activity levels, and responses to questionnaires.

Start Date26 May 2025

Sponsor / Collaborator

Universidade Nova de Lisboa

NCT06794515

/ Not yet recruitingNot ApplicableIIT

Metabolic Effects of cGMP: From Amino Acid Absorption Kinetics to Appetite Modulation

Phenylketonuria is an inborn error of phenylalanine metabolism. Although the phenylalanine-restricted diet is recognized as the mainstay of therapy, little is known about the impact of protein substitutes on the metabolism of patients with phenylketonuria.
Therefore, the aim of this project is to study the impact of acute ingestion of casein glycomacropeptide supplemented with amino acids (cCGMP-AAs) alone or in combination with two different meals on amino acid absorption kinetics, glycaemic and insulinemic response, and on acute markers of appetite control.
The main findings of this project will bring new insights into the dietary management of these patients, which may lead to improvements in protein substitutes formulations.

Start Date03 Feb 2025

Sponsor / Collaborator

Universidade Nova de Lisboa

100 Clinical Results associated with Universidade Nova de Lisboa

0 Patents (Medical) associated with Universidade Nova de Lisboa

17,486

Literatures (Medical) associated with Universidade Nova de Lisboa

01 Jan 2026·TALANTA

Novel tissue markers in renal neoplasms using molar-scale quantitative proteomics via the total protein approach normalised with protein deglycase DJ-1 (PARK7)

Article

Author: Dhir, Rajiv ; Carvalho, Luís B ; Capelo, José L ; Santos, Hugo M ; Figueiredo, André Q ; Wiśniewski, Jacek R ; Domingos, Inês F ; Quiroga-Garza, Gabriela ; Lodeiro, Carlos ; Korentzelos, Dimitrios

Mass spectrometry-based proteomics enables large-scale protein quantification but is hindered by inter- and intra-laboratory variability, complicating data integration and biomarker discovery. This study aims to develop an optimised normalisation strategy using the ubiquitously expressed protein deglycase DJ-1 (PARK7) as an internal standard, combined with the Total Protein Approach (TPA) to improve data comparability in renal neoplasms proteomic datasets. We analysed the MS-based proteomics data of renal tissues from clear cell renal cell carcinoma (ccRCC, n = 7), papillary renal cell carcinoma (pRCC, n = 5), chromophobe renal cell carcinoma (chRCC, n = 5), renal oncocytoma (RO, n = 5), and control normal adjacent tissue (NAT, n = 5). Protein concentrations were calculated using the Total Protein Approach, and the data were normalised to PARK7 expression using a TPA reference value of 34.1 pmol/mg. TPA-PARK7 normalisation showed a trend towards reducing interquartile ranges. After normalisation, 95 % of biomarkers from non-normalised datasets remained statistically significant. Among these, 31 % of previously proposed candidate biomarkers retained their ability to distinguish between conditions, with histologically validated biomarkers (TUBB3, LAMP1, and HK1) showing improved differentiation. Additionally, 322 new statistically significant proteins were identified, and 18 new potential biomarkers for renal neoplasm were detected exclusively after TPA-PARK7 normalisation. Our findings demonstrate that using PARK7 as an internal standard, combined with the TPA, significantly enhances the statistical robustness and reliability of protein quantification in mass spectrometry-based proteomics. This normalisation strategy reduces interlaboratory variability, preserves biomarker differentiation capability, and enables novel biomarker discovery. By reducing variability, this method enhances cross-study comparability and supports the advancement of clinically relevant biomarker discovery.

31 Dec 2025·Pulmonology

Smoking-attributable mortality in Portugal and its regions in 2019

Article

Author: Ravara, S. ; Pérez-Ríos, M. ; Varela-Lema, L. ; Santiago-Pérez, M.I. ; Ruano-Ravina, A. ; Mourino, N. ; López-Vizcaíno, E. ; Aguiar, P. ; Rey-Brandariz, J. ; Candal-Pedreira, C.

INTRODUCTION AND OBJECTIVES:

Timely regional-specific estimates of smoking-attributable mortality (SAM) are crucial for healthcare planning and tobacco control advocacy. Currently, this information is lacking in Portugal. The aim of this study was to estimate SAM by region in 2019 among the Portuguese population aged ≥35 years.

METHODS:

SAM was estimated using an independent-prevalence method. Observed mortality was obtained from Portugal Statistics; lung cancer mortality rates in smokers and never-smokers from the Cancer Prevention Study I-II and updated relative risks from five contemporary US cohort studies. SAM was estimated for each NUTS-II region by sex, age, and cause of death. Crude SAM rates, sex and age-specific rates, and age-adjusted rates were calculated using the direct method.

RESULTS:

In 2019, tobacco consumption caused 13,847 deaths, representing 12.3% of total mortality among the Portuguese population aged ≥35 years. Of the total SAM, 71.2% occurred in men and 22.2% in those under 65 years; 42.5% was due to cancer, 35.4% to cardiovascular and metabolic diseases, and 22.2% to respiratory diseases. SAM greatly varied among regions from 2.1% in Madeira to 36.2% in the North region. In men, cancer was the leading cause of death in all regions, while in women it was cardiovascular and metabolic diseases.

CONCLUSION:

In Portugal, tobacco-mortality burden is high and varies significantly by region, sex and age. Therefore, estimates disaggregated by sociodemographic data and region may better support decision-makers while tailoring and implementing tobacco control policies addressing health population needs. The apparent lower tobacco burden among women and in some Portuguese regions may dramatically rise in the near future. This and the high SAM in Portugal, particularly in some regions, highlights the need to accelerate tobacco control both at national and regional levels.

31 Dec 2025·Pulmonology

Quality of life associated with breathlessness in the multinational Burden of Obstructive Lung Disease (BOLD) study: A cross-sectional analysis

Article

Author: Rashid, Abdul ; Franssen, Frits M E ; Janssen, Daisy J A ; Seemungal, Terence ; Cherkaski, Hamid Hacene ; Rodrigues, Maria Fatima ; Paraguas, Stefanni Nonna ; Ahmed, Rana ; Denguezli, Meriam ; El Rhazi, Karima ; Nielsen, Rune ; Jõgi, Rain ; Potts, James ; Elsony, Asma ; Mortimer, Kevin ; Mannino, David ; Burney, Peter ; Wouters, Emiel F M ; Hartl, Sylvia ; Cardoso, Joao ; Amaral, André F S ; Janson, Christer ; Erhabor, Gregory ; Harrabi, Imed ; Anand, Mahesh Padukudru ; Studnicka, Michael ; Nafees, Asaad ; Bárbara, Cristina ; Biaze, Mohammed El ; Agarwal, Dhiraj ; Juvekar, Sanjay ; Obaseki, Daniel ; Müller, Alexander ; Gíslason, Thorarinn ; Koul, Parvaiz ; Dias, Herminia Brites ; Al Ghobain, Mohammed

INTRODUCTION:

Evidence of an association between breathlessness and quality of life from population-based studies is limited. We aimed to investigate the association of both physical and mental quality of life with breathlessness across several low-, middle- and high-income countries.

METHODS:

We analysed data from 19 714 adults (31 sites, 25 countries) from the Burden of Obstructive Lung Disease (BOLD) study. We measured both mental and physical quality of life components using the SF-12 questionnaire, and defined breathlessness as grade ≥2 on the modified Medical Research Council scale. We used multivariable linear regression to assess the association of each quality-of-life component with breathlessness. We pooled site-specific estimates using random-effects meta-analysis.

RESULTS:

Both physical and mental component scores were lower in participants with breathlessness compared to those without. This association was stronger for the physical component (coefficient = -7.59; 95%CI -8.60, -6.58; I² = 78.5%) than for the mental component (coefficient = -3.50; 95%CI -4.36, -2.63; I² = 71.4%). The association between physical component and breathlessness was stronger in high-income countries (coefficient = -8.82; 95%CI -10.15, -7.50). Heterogeneity across sites was partly explained by sex and tobacco smoking.

CONCLUSION:

Quality of life is worse in people with breathlessness, but this association varies widely across the world.

News (Medical) associated with Universidade Nova de Lisboa

08 Feb 2021

·www.biospace.com

Rute Fernandes Appointed General Manager of Takeda Canada

TORONTO, Feb. 8, 2021 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Rute Fernandes as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Ms. Fernandes has held a number of executive roles in business development, commercial strategy operations, and country management over her 22-year career in the pharmaceutical industry. Most recently, she served as Takeda's Group Vice-President and Head of Rare Disease Franchise for Europe and Canada, responsible for a portfolio of more than 15 brands across three disease areas—namely Rare Metabolic Disorders, Rare Hematology, and Rare Hereditary Angioedema and Transplants—in a total of 38 countries. "Rute is an inspiring leader who has acquired broad experience in senior management roles and a deep understanding of rare diseases internationally," said Giles Platford, President of the Europe and Canada Business Unit at Takeda. "Canada is a critical market for Takeda's global operations and I am confident that under Rute's leadership, Takeda will strengthen our position as a leading biopharmaceutical company in the country, delivering highly innovative medicines and transformative care to Canadians." Takeda is a global, values-based, R&D-driven biopharmaceutical company with an unwavering commitment to bringing Better Health and a Brighter Future to people around the world. Established in Canada in 2009, Takeda is one of the fastest-growing pharmaceutical companies in Canada and a leader in the treatment of rare diseases. "I am delighted to have been selected to lead Takeda Canada and work alongside the many talented individuals that make up the Canadian Team," said Rute Fernandes. "This is an important time for our industry in Canada, and I look forward to ensuring sustainable access to innovative medicines for Canadians who need them most." Ms. Fernandes holds a Master's in Economics from the Nova School of Business & Economics and an MBA from HEC Lausanne. About Takeda Canada Inc. Takeda Canada Inc. is the Canadian marketing and sales organization of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. Additional information about Takeda Canada is available at SOURCE Takeda Canada, Inc. Company Codes: NYSE:TAK, Tokyo:4502

Vaccine

100 Deals associated with Universidade Nova de Lisboa

100 Translational Medicine associated with Universidade Nova de Lisboa

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Current Projects

Drug(Targets)	Indications	Global Highest Phase

WO2023187607 Patent Mining	Autoimmune Diseases More	Discovery
WO2023156983 ( CCL17 )Patent Mining	Nervous System Diseases More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis